Physician profile
Ramon MD Ramirez
NPI 1396844478
$3,530.95
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $626 · 2021: $606 · 2022: $493 · 2023: $597 · 2024: $39.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $989.10 | 2019-2023 | Dovato, Rukobia, Cabenuva |
| Janssen Products, Lp | $885.56 | 2019-2023 | Symtuza |
| Insmed, INC. | $358.47 | 2019-2023 | Arikayce |
| Allergan, INC. | $284.37 | 2019-2020 | |
| Janssen Biotech, INC. | $255.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $174.11 | 2019-2021 | |
| Abbvie INC. | $139.38 | 2021 | |
| Gilead Sciences, INC. | $111.31 | 2019-2024 | |
| Comsort, INC | $100.00 | 2019 | |
| Astellas Pharma US INC | $77.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $65.26 | 2023 | Xarelto |
| Cumberland Pharmaceuticals, INC. | $41.35 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $19.75 | 2019 | |
| Nabriva Therapeutics, Plc | $17.34 | 2020 | |
| Shionogi INC | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.